- Reuters•last year
Ten weeks after closing its $8.4 billion purchase of Synageva BioPharma Corp, Alexion Pharmaceuticals Inc on Tuesday announced European approval for the key drug acquired through the deal, an enzyme-replacement therapy for an ultra-rare, life threatening disease. The treatments are awaiting U.S. approval decisions after receiving breakthrough therapy designations from the Food and Drug Administration. "This is sort of a momentous year for us," Alexion Chief Executive David Hallal said in an interview.
- TheStreet.com•last year
These stocks have had a really good run, says Wedbush Securities, which is holding its annual health care investment conference in New York.
Synageva BioPharma Corp. (GEVA)
NasdaqGS - NasdaqGS Delayed Price. Currency in USD
As of 3:59 PM EDT. Market open.
|Day's Range||0.00 - 0.00|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||N/A|
|Avg Vol (3m)||N/A|
|Dividend & Yield||N/A (N/A)|